Tyra Biosciences Q1 net loss $28.1M; cash $318.9M; BEACH301 achondroplasia study open

Tyra Biosciences, Inc.

2025-Q1 EPS reported -$0.47

Net loss $28.1M vs $18.2M in Q1 2024; R&D expense $25.0M (up 45% YoY) driven by clinical start-up costs.
Cash, equivalents, and marketable securities $318.9M as of March 31, 2025; runway through at least 2027.
BEACH301 Phase 2 study of TYRA-300 for pediatric achondroplasia now enrolling safety sentinel cohort.
SURF431 Phase 1 study of TYRA-430 (FGFR4/3 inhibitor) in HCC initiated; first patient dosed.
SURF302 Phase 2 NMIBC study of TYRA-300 expected to dose first patient in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.